Authors: Peter Czuczman, Andrew L. Lewis, Rhys Whomsley, Z. A. Bascal, Alban Denys, David Grey, Hugh Kilpatrick
Source:
Theranostics
Theranostics, vol. 7, no. 8, pp. 2164-2176
Subject Terms: Research Paper, Vandetanib-eluting Radiopaque Beads, pharmacokinetics, safety and toxicity, Pharmacology, Toxicology and Pharmaceutics (miscellaneous), Medicine (miscellaneous), Distribution (pharmacology), Metabolite, chemistry.chemical_compound, chemistry, Artery, medicine.anatomical_structure, medicine, Pharmacology, Pharmacokinetics, Toxicity, business.industry, business, Vandetanib, medicine.drug, Embolization, medicine.medical_treatment, Cmax, Animals, Contrast Media/administration & dosage, Contrast Media/adverse effects, Contrast Media/pharmacokinetics, Embolization, Therapeutic/methods, Injections, Intra-Arterial, Liver/diagnostic imaging, Liver/pathology, Models, Animal, Piperidines/administration & dosage, Piperidines/adverse effects, Piperidines/pharmacokinetics, Quinazolines/administration & dosage, Quinazolines/adverse effects, Quinazolines/pharmacokinetics, Radiography, Abdominal, Swine, Tomography, X-Ray Computed
File Description: application/pdf
Access URL:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c26d962737625d69577515e2d40c2ea1
http://europepmc.org/articles/PMC5505051
Authors: Kunwar Shailubhai, Jean-Charles Soria, Antoine Hollebecque, Christophe Massard, Rastilav Bahleda, Anas Gazzah, Sandrine Aspeslagh, Michele Reni, Anna Spreafico, Andrea Varga
Contributors: Aspeslagh, S, Shailubhai, K, Bahleda, R, Gazzah, A, Varga, A, Hollebecque, A, Massard, C, Spreafico, A, Reni, M, Soria, J-C, Medical Oncology
Subject Terms: Pharmacology (medical), Cancer Research, Pharmacology, Toxicology, Oncology, Regimen, Gemcitabine, medicine.drug, medicine, Tolerability, medicine.medical_specialty, Internal medicine, Gastroenterology, Neutropenia, medicine.disease, Pharmacokinetics, Concomitant, Refractory, Peritoneal mesothelioma, business.industry, business, Aged, Antimetabolites, Antineoplastic/administration & dosage, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Carcinoma, Non-Small-Cell Lung/drug therapy, Cyclin-Dependent Kinases/antagonists & inhibitors, Deoxycytidine/administration & dosage, Drug Interactions, Drug Resistance, Neoplasm, Female, Humans, Lung Neoplasms/drug therapy, Male, Maximum Tolerated Dose, Middle Aged, Neoplasms/drug therapy, Pyrazoles/administration & dosage, Quinazolines/administration & dosage, Treatment Outcome
Access URL: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::42306b90b467bedc036686d59e41b35d
Authors: Martina Uttenreuther-Fischer, Peter Stopfer, Ahmad Awada, Alain Hendlisz, Frank Fleischer, Patrick Schöffski, T. Besse-Hammer, Herlinde Dumez, Martine Piccart, Pascal Wolter
Source:
Investigational New Drugs
Investigational new drugs, 31 (3
Subject Terms: Phase I Studies, Phase I, BIBW 2992, Afatinib, Epidermal growth factor receptor, Tyrosine kinase inhibitor, Pharmacokinetics, neoplasms, Pharmacology (medical), Pharmacology, Oncology, Rash, medicine.symptom, medicine, medicine.medical_specialty, Adverse effect, Toxicity, business.industry, business, Stomatitis, medicine.disease, Internal medicine, medicine.drug, Clinical trial, Docetaxel, Cancérologie, Adult, Aged, Antineoplastic Agents -- administration & dosage -- adverse effects -- pharmacokinetics, Antineoplastic Combined Chemotherapy Protocols -- administration & dosage -- adverse effects -- pharmacokinetics, Drug Administration Schedule, Female, Gastrointestinal Diseases -- chemically induced, Humans, Male, Maximum Tolerated Dose, Middle Aged, Neoplasms -- blood -- drug therapy, Quinazolines -- administration & dosage -- adverse effects -- pharmacokinetics, Skin Diseases -- chemically induced, Taxoids -- administration & dosage -- adverse effects -- pharmacokinetics, Science & Technology, Life Sciences & Biomedicine, Pharmacology & Pharmacy, CELL LUNG-CANCER, KINASE INHIBITOR, GEFITINIB, ERLOTINIB, TRIAL, CARBOPLATIN, PACLITAXEL, BIBW-2992, LINES
File Description: 1 full-text file(s): application/pdf; Print-Electronic
Access URL:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ed9ba982df0332356cd898f91dd30e4
http://europepmc.org/articles/PMC3644400
Authors: William Bumgardner, Joel Miller, Les H. Brail, Nadine Houede, Karim A. Benhadji, Paul Westwood, Antoine Hollebecque, Christophe Massard, Jean-Charles Soria, Antoine Italiano, Ezra E.W. Cohen
Contributors: Département d’Innovation Thérapeutique et essais précoces [Gustave Roussy] (DITEP), Institut Gustave Roussy (IGR), Oncologie digestive, Département de médecine oncologique [Gustave Roussy], Institut Gustave Roussy (IGR)-Institut Gustave Roussy (IGR), Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Institut Bergonié [Bordeaux], UNICANCER, Institut de recherche en cancérologie de Montpellier (IRCM - U896 Inserm - UM1), Université Montpellier 1 (UM1)-CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Département de radiothérapie [Gustave Roussy]
Source:
European Journal of Cancer
European Journal of Cancer, Elsevier, 2014, 50, pp.876--84. ⟨10.1016/j.ejca.2013.12.006⟩
Subject Terms: Humans, Female, Middle Aged, Adult, Male, Treatment Outcome, Aged, Time Factors, Drug Administration Schedule, Adaptor Proteins, Signal Transducing/metabolism, Anorexia/chemically induced, Antineoplastic Combined Chemotherapy Protocols/adverse, Area Under Curve, Diarrhea/chemically induced, Dose-Response Relationship, Drug, effects/pharmacokinetics, effects/pharmacokinetics/*therapeutic use, Fatigue/chemically induced, Metabolic Clearance Rate, Neoplasms/*drug therapy/metabolism/pathology, Protein Kinase Inhibitors/administration & dosage/adverse, Proto-Oncogene Proteins c-akt/metabolism, Pyrazoles/administration & dosage/adverse effects/pharmacokinetics, Pyrimidines/administration & dosage/adverse effects/pharmacokinetics, Quinazolines/administration & dosage/adverse effects, Ribosomal Protein S6 Kinases, 70-kDa/*antagonists & inhibitors/metabolism, Sirolimus/administration & dosage/adverse effects/analogs & derivatives, Vomiting/chemically induced, [SDV.CAN]Life Sciences [q-bio]/Cancer, Cancer Research, Oncology, medicine.medical_specialty, medicine, Clotting factor, Everolimus, medicine.drug, Erlotinib, Nausea, medicine.symptom, Pharmacokinetics, Pharmacology, Adverse effect, Internal medicine, business.industry, business, Vomiting, Common Terminology Criteria for Adverse Events
Access URL:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8c3a7a2858a536425a05890e5690b8d2
https://hal.umontpellier.fr/hal-02168061
Authors: Antonella Ferro, Catherine E. Ellis, Juan Carlos Toral-Peña, Claudia Aura, Ghizlane Rouas, Holger Eidtmann, Françoise Rothé, Christos Sotiriou, Geraldine Gebhart, Michail Ignatiadis, Malcolm Bavington, Evandro de Azambuja, Marion Maetens, Cristina Gamez, Hervé Cure, Peter Vuylsteke, Hatem A. Azim, José Baselga, Serena Di Cosimo, Martine Piccart-Gebhart, Julien Domont
Source: Breast, 22 (6
Subject Terms: Sciences biomédicales, Cancérologie, Médecine pathologie humaine, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Humanized -- administration & dosage, Antineoplastic Combined Chemotherapy Protocols -- therapeutic use, Breast Neoplasms -- chemistry -- drug therapy -- pathology, Chemotherapy, Adjuvant, Female, Humans, Middle Aged, Molecular Targeted Therapy, Neoadjuvant Therapy, Neoplastic Cells, Circulating -- chemistry -- pathology, Paclitaxel -- administration & dosage, Quinazolines -- administration & dosage, Receptor, ErbB-2 -- analysis -- antagonists & inhibitors, Young Adult, skin and connective tissue diseases, mental disorders, General Medicine, Surgery, Lapatinib, medicine.drug, medicine, Trastuzumab, Gynecology, medicine.medical_specialty, business.industry, business, Targeted therapy, medicine.medical_treatment, Neoadjuvant therapy, Gastroenterology, In patient, Circulating tumor cell, Internal medicine, Paclitaxel, chemistry.chemical_compound, chemistry, Breast cancer, medicine.disease, neoplasms
File Description: 2 full-text file(s): application/pdf; application/pdf
Access URL:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::762fb130005a634adcc13840b62694c1
http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/157832
Source: European journal of cancer, 89
Index Terms: Cancérologie, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols -- therapeutic use, Breast -- diagnostic imaging, Breast Neoplasms -- chemistry -- diagnostic imaging -- drug therapy -- mortality, Female, Humans, Lapatinib, Mammography, Middle Aged, Neoadjuvant Therapy, Quinazolines -- administration & dosage -- therapeutic use, Receptor, ErbB-2 -- analysis, Trastuzumab -- administration & dosage -- therapeutic use, Breast ultrasound, HER2 positive breast cancer, Neoadjuvant, Targeted therapy, info:eu-repo/semantics/article, info:ulb-repo/semantics/articlePeerReview, info:ulb-repo/semantics/openurl/article
URL:
Source: Cancer treatment reviews, 57
Index Terms: Cancérologie, Imagerie médicale, radiologie, tomographie, Antineoplastic Combined Chemotherapy Protocols -- therapeutic use, Breast Neoplasms -- drug therapy -- enzymology -- immunology -- pathology, Chemotherapy, Adjuvant, Female, Humans, Lapatinib, Lymphocytes, Tumor-Infiltrating -- drug effects -- immunology -- pathology, Neoadjuvant Therapy, Quinazolines -- administration & dosage, Randomized Controlled Trials as Topic, Receptor, ErbB-2 -- antagonists & inhibitors -- biosynthesis, Trastuzumab -- administration & dosage, HER2-postive breast cancer, Neoadjuvant treatment, Pathologic complete response, Trastuzumab, Tumor-infiltrating lymphocytes, info:eu-repo/semantics/article, info:ulb-repo/semantics/articlePeerReview, info:ulb-repo/semantics/openurl/article
URL:
Source: Journal of clinical oncology, 32 (29
Index Terms: Cancérologie, Médecine pathologie humaine, Sciences bio-médicales et agricoles, Adult, Aged, Anthracyclines -- administration & dosage, Antibodies, Monoclonal, Humanized -- administration & dosage, Antineoplastic Combined Chemotherapy Protocols -- therapeutic use, Breast Neoplasms -- drug therapy -- genetics -- pathology, Exons, Female, Genotype, Humans, Middle Aged, Mutation, Neoadjuvant Therapy, Phosphatidylinositol 3-Kinases -- genetics, Quinazolines -- administration & dosage, Randomized Controlled Trials as Topic, Receptor, ErbB-2 -- antagonists & inhibitors -- genetics, Taxoids -- administration & dosage, Treatment Outcome, Tumor Markers, Biological -- analysis, info:eu-repo/semantics/article, info:ulb-repo/semantics/articlePeerReview, info:ulb-repo/semantics/openurl/article
URL:
Source: Journal of clinical oncology, 32 (29
Index Terms: Cancérologie, Médecine pathologie humaine, Sciences bio-médicales et agricoles, Adult, Aged, Anthracyclines -- administration & dosage, Antibodies, Monoclonal, Humanized -- administration & dosage, Antineoplastic Combined Chemotherapy Protocols -- therapeutic use, Breast Neoplasms -- drug therapy -- genetics -- pathology, Exons, Female, Genotype, Humans, Middle Aged, Mutation, Neoadjuvant Therapy, Phosphatidylinositol 3-Kinases -- genetics, Quinazolines -- administration & dosage, Randomized Controlled Trials as Topic, Receptor, ErbB-2 -- antagonists & inhibitors -- genetics, Taxoids -- administration & dosage, Treatment Outcome, Tumor Markers, Biological -- analysis, info:eu-repo/semantics/article, info:ulb-repo/semantics/articlePeerReview, info:ulb-repo/semantics/openurl/article
URL:
Source: Breast cancer research and treatment, 143 (3
Index Terms: Cancérologie, Antibodies, Monoclonal, Humanized -- administration & dosage, Breast Neoplasms -- drug therapy -- genetics -- pathology, Early Detection of Cancer, Estrogen Receptor alpha -- genetics -- metabolism, Female, Humans, Immunohistochemistry, In Situ Hybridization, Fluorescence, Italy, Quinazolines -- administration & dosage, Receptor, ErbB-2 -- genetics -- metabolism, Tumor Markers, Biological -- genetics, Breast cancer, Central laboratory review, Estrogen receptor testing, HER2 testing, Local versus central laboratory concordance, info:eu-repo/semantics/article, info:ulb-repo/semantics/articlePeerReview, info:ulb-repo/semantics/openurl/article
URL:
Source: Breast, 22 (6
Index Terms: Sciences biomédicales, Cancérologie, Médecine pathologie humaine, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Humanized -- administration & dosage, Antineoplastic Combined Chemotherapy Protocols -- therapeutic use, Breast Neoplasms -- chemistry -- drug therapy -- pathology, Chemotherapy, Adjuvant, Female, Humans, Middle Aged, Molecular Targeted Therapy, Neoadjuvant Therapy, Neoplastic Cells, Circulating -- chemistry -- pathology, Paclitaxel -- administration & dosage, Quinazolines -- administration & dosage, Receptor, ErbB-2 -- analysis -- antagonists & inhibitors, Young Adult, info:eu-repo/semantics/article, info:ulb-repo/semantics/articlePeerReview, info:ulb-repo/semantics/openurl/article
URL:
Source: Annals of oncology, 24 (12
Index Terms: Cancérologie, Médecine pathologie humaine, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols -- pharmacology -- therapeutic use, Brain Neoplasms -- drug therapy -- metabolism -- mortality -- secondary, Breast Neoplasms -- drug therapy -- metabolism -- mortality -- pathology, Dacarbazine -- administration & dosage -- analogs & derivatives, Disease-Free Survival, Female, Humans, Maximum Tolerated Dose, Middle Aged, Quinazolines -- administration & dosage, Receptor, ErbB-2 -- metabolism, Treatment Outcome, info:eu-repo/semantics/article, info:ulb-repo/semantics/articlePeerReview, info:ulb-repo/semantics/openurl/article
URL:
Source: Investigational new drugs, 31 (3
Index Terms: Cancérologie, Adult, Aged, Antineoplastic Agents -- administration & dosage -- adverse effects -- pharmacokinetics, Antineoplastic Combined Chemotherapy Protocols -- administration & dosage -- adverse effects -- pharmacokinetics, Drug Administration Schedule, Female, Gastrointestinal Diseases -- chemically induced, Humans, Male, Maximum Tolerated Dose, Middle Aged, Neoplasms -- blood -- drug therapy, Quinazolines -- administration & dosage -- adverse effects -- pharmacokinetics, Skin Diseases -- chemically induced, Taxoids -- administration & dosage -- adverse effects -- pharmacokinetics, Afatinib, BIBW 2992, Epidermal growth factor receptor, Pharmacokinetics, Phase I, Tyrosine kinase inhibitor, info:eu-repo/semantics/article, info:ulb-repo/semantics/articlePeerReview, info:ulb-repo/semantics/openurl/article
URL:
Source: Journal of clinical oncology, 31 (36
Index Terms: Cancérologie, Adult, Age Factors, Aged, Antibodies, Monoclonal, Humanized -- administration & dosage -- adverse effects, Antineoplastic Agents -- administration & dosage -- adverse effects, Antineoplastic Combined Chemotherapy Protocols -- adverse effects, Breast Neoplasms -- chemistry -- drug therapy -- pathology, Chemotherapy, Adjuvant, Diarrhea -- chemically induced, Drug Administration Schedule, Drug Eruptions -- etiology, Drug-Induced Liver Injury -- etiology, Female, Humans, Incidence, Logistic Models, Middle Aged, Neoadjuvant Therapy -- methods, Paclitaxel -- administration & dosage, Quinazolines -- administration & dosage -- adverse effects, Receptor, ErbB-2 -- analysis, Time Factors, Tumor Markers, Biological -- analysis, info:eu-repo/semantics/article, info:ulb-repo/semantics/articlePeerReview, info:ulb-repo/semantics/openurl/article
URL:
Source: Lancet oncology, 14 (1
Index Terms: Cancérologie, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Humanized -- administration & dosage, Breast Neoplasms -- drug therapy -- pathology, Chemotherapy, Adjuvant -- adverse effects, Disease-Free Survival, Drug-Related Side Effects and Adverse Reactions -- chemically induced -- classification, Female, Humans, Lymph Nodes -- pathology, Middle Aged, Neoplasm Staging, Quinazolines -- administration & dosage -- adverse effects, Receptor, ErbB-2 -- metabolism, info:eu-repo/semantics/article, info:ulb-repo/semantics/articlePeerReview, info:ulb-repo/semantics/openurl/article
URL:
Source: European journal of cancer, 49 (18
Index Terms: Cancérologie, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols -- adverse effects -- therapeutic use, Breast Neoplasms -- drug therapy -- metabolism -- pathology, Deoxycytidine -- administration & dosage -- adverse effects -- analogs & derivatives, Diarrhea -- chemically induced, Disease-Free Survival, Drug Administration Schedule, Female, Fluorouracil -- administration & dosage -- adverse effects -- analogs & derivatives, Humans, Kaplan-Meier Estimate, Middle Aged, Nausea -- chemically induced, Quinazolines -- administration & dosage -- adverse effects, Quinolines -- adverse effects -- therapeutic use, Receptor, ErbB-2 -- metabolism, Treatment Outcome, Vomiting -- chemically induced, Breast, phase II, info:eu-repo/semantics/article, info:ulb-repo/semantics/articlePeerReview, info:ulb-repo/semantics/openurl/article
URL:
Source: The oncologist, 18 (2
Index Terms: Cancérologie, Antibodies, Monoclonal, Humanized -- administration & dosage -- therapeutic use, Antineoplastic Combined Chemotherapy Protocols -- therapeutic use, Breast Neoplasms -- drug therapy -- pathology, Clinical Trials, Phase III as Topic -- methods, Female, Humans, International Cooperation, Multicenter Studies as Topic -- methods, Quinazolines -- administration & dosage, Randomized Controlled Trials as Topic -- methods, Time Factors, Activation, Ethics committee/institutional review board, Phase III clinical trials, info:eu-repo/semantics/article, info:ulb-repo/semantics/articlePeerReview, info:ulb-repo/semantics/openurl/article
URL:
Source: The Journal of nuclear medicine, 54 (11
Index Terms: Sciences bio-médicales et agricoles, Antibodies, Monoclonal, Humanized -- administration & dosage -- therapeutic use, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms -- diagnosis -- drug therapy -- metabolism, Female, Fluorodeoxyglucose F18 -- diagnostic use, Humans, Neoadjuvant Therapy, Positron-Emission Tomography, Quinazolines -- administration & dosage -- therapeutic use, Receptor, ErbB-2 -- metabolism, Time Factors, Tomography, X-Ray Computed, Treatment Outcome, Tumor Markers, Biological -- metabolism, 18F-FDG-PET/CT, anti-HER2 drugs, early response assessment, info:eu-repo/semantics/article, info:ulb-repo/semantics/articlePeerReview, info:ulb-repo/semantics/openurl/article
URL:
Source: Lancet oncology, 14 (1
Index Terms: Cancérologie, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Humanized -- administration & dosage, Breast Neoplasms -- drug therapy -- pathology, Chemotherapy, Adjuvant -- adverse effects, Disease-Free Survival, Drug-Related Side Effects and Adverse Reactions -- chemically induced -- classification, Female, Humans, Lymph Nodes -- pathology, Middle Aged, Neoplasm Staging, Quinazolines -- administration & dosage -- adverse effects, Receptor, ErbB-2 -- metabolism, info:eu-repo/semantics/article, info:ulb-repo/semantics/articlePeerReview, info:ulb-repo/semantics/openurl/article
URL:
Source: The Journal of nuclear medicine, 54 (11
Index Terms: Sciences bio-médicales et agricoles, Antibodies, Monoclonal, Humanized -- administration & dosage -- therapeutic use, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms -- diagnosis -- drug therapy -- metabolism, Female, Fluorodeoxyglucose F18 -- diagnostic use, Humans, Neoadjuvant Therapy, Positron-Emission Tomography, Quinazolines -- administration & dosage -- therapeutic use, Receptor, ErbB-2 -- metabolism, Time Factors, Tomography, X-Ray Computed, Treatment Outcome, Tumor Markers, Biological -- metabolism, 18F-FDG-PET/CT, anti-HER2 drugs, early response assessment, info:eu-repo/semantics/article, info:ulb-repo/semantics/articlePeerReview, info:ulb-repo/semantics/openurl/article
URL: